Skip to content
AnalystLens

Medpace Holdings Quarterly Report for Q3 Ended Sep 30, 2026

Filing Date
Filed October 22, 2026
Period End
September 30, 2026
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Change in control8-K · Jun ’17Jun ’17
  2. Leadership change8-K · May ’19May ’19
  3. Leadership change8-K · Jul ’21Jul ’21
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 10-Q filed October 22, 2026. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. reported third-quarter 2026 revenue, net of $716.0 milliona, up from $659.9 million in the prior-year quarter, and net income of $137.5 million, compared with $111.1 million.

For the nine months ended September 30, 2026, revenue was $2,129.9 millionb versus $1,821.8 million, and net income was $382.7 million versus $316.0 million. Diluted EPS was $4.84 for the quarter and $13.37 for the nine months. The filing states that growth was primarily driven by the Metabolic, Oncology and Central Nervous System therapeutic areas.

Net new business awards were $873.4 millionc for the quarter and $2,287.6 million for the nine months, and backlog was $3,167.2 million as of September 30, 2026. The balance sheet strengthened over the period. Cash and cash equivalents rose to $705.3 million from $497.0 million at year-end 2025, and the company had no indebtedness.

Operating cash flow was $530.4 milliond for the nine months. Share repurchases totaled $294.7 million in the nine months, with no repurchases in the third quarter. Effective October 20, 2026, the Board terminated the existing authorization and approved a new repurchase authorization of up to $1.0 billion.

The filing also discloses securities class action and derivative lawsuits filed in 2026 relating to statements about the company's book-to-bill ratio. The plaintiffs voluntarily dismissed the actions, without prejudice, in October 2026. Management stated that legal proceedings were immaterial as of September 30, 2026.

Key Highlights

  1. Q3 2026 revenue, net rose to $716.0 million from $659.9 million; nine-month revenue was $2,129.9 million versus $1,821.8 million.
  2. Q3 2026 net income was $137.5 million (diluted EPS $4.84), versus $111.1 million (diluted EPS $3.86) in Q3 2025.
  3. Backlog was $3,167.2 million as of September 30, 2026, up from $3,000.6 million a year earlier; net new business awards were $873.4 million for the quarter.
  4. Cash and cash equivalents increased to $705.3 million from $497.0 million at December 31, 2025, and the company reported no indebtedness.
  5. Nine-month operating cash flow was $530.4 million; $294.7 million was used to repurchase 705,616 shares.
  6. Effective October 20, 2026, the Board terminated the prior repurchase authorization and approved a new authorization of up to $1.0 billion.
  7. Two stockholder derivative suits and one securities class action tied to book-to-bill ratio statements were voluntarily dismissed without prejudice in October 2026.

Financial Statements

Q3 FY2026 against Q3 FY2025

Line itemQ3 FY2026Q3 FY2025Change
Revenue$716.00M$659.90M+8.5%
SG&A Expenses$51.77M$48.08M+7.7%
Operating Expenses$550.46M$518.10M+6.2%
Operating Income$165.54M$141.81M+16.7%
Net Income$137.46M$111.14M+23.7%
EPS (Basic)$4.92$3.95+24.6%
EPS (Diluted)$4.84$3.86+25.4%
Shares Outstanding (Basic)27.94M28.14M−0.7%
Shares Outstanding (Diluted)28.37M28.82M−1.5%

Frequently Asked Questions

  1. How did Medpace perform in the third quarter of 2026?

    Revenue, net was $716.0 million, up from $659.9 million a year earlier. Income from operations was $165.5 million, up from $141.8 million, and net income was $137.5 million, up from $111.1 million. Diluted EPS was $4.84 compared with $3.86.

  2. What drove revenue growth?

    The filing states that the increase for the three and nine months ended September 30, 2026 was primarily driven by growth within the Metabolic, Oncology and Central Nervous System therapeutic areas. Reimbursed out-of-pocket expenses, which fluctuate with program timing, also rose significantly and were a major part of the increase in total direct costs.

  3. How strong is the company's backlog and new business activity?

    Backlog was $3,167.2 million as of September 30, 2026, up $166.6 million from $3,000.6 million a year earlier. Net new business awards were $873.4 million for the quarter and $2,287.6 million for the nine months. Approximately $1,980.0 million to $2,000.0 million of backlog is expected to convert to net revenue over the next twelve months.

  4. What is the company's capital allocation outlook?

    The company repurchased $294.7 million of stock in the first nine months of 2026 and made no repurchases in the third quarter. Effective October 20, 2026, the Board approved a new share repurchase authorization of up to $1.0 billion. Capital expenditures were $50.9 million for the nine months, and the company stated its liquidity is sufficient for the next 12 months.

  5. Are there material legal risks disclosed in the filing?

    The filing discloses class action and derivative lawsuits filed in 2026 concerning statements about the book-to-bill ratio. The plaintiffs voluntarily dismissed these actions, without prejudice, in October 2026. Management stated that legal proceedings were immaterial as of September 30, 2026.